A three-year study of GA Depot, a monthly injection for primary progressive multiple sclerosis (PPMS), found that most patients experienced no disability progression, with some even showing slight improvements in mobility. These interim results from a Phase 2a clinical trial will be presented tomorrow by developer Mapi Pharma at the Americas Committee for Treatment and […]
The post ACTRIMS 2026: GA Depot shot keeps disability stable for most PPMS patients appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com